vs
MYRIAD GENETICS INC（MYGN）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是MYRIAD GENETICS INC的3.3倍（$699.9M vs $209.8M）。MYRIAD GENETICS INC同比增速更快（-0.4% vs -3.7%）。过去两年MYRIAD GENETICS INC的营收复合增速更高（1.9% vs -2.9%）
麦利亚德基因公司是总部位于美国犹他州盐湖城的美国基因检测与精准医疗企业。公司拥有多项自主专利技术，帮助医生与患者了解人类疾病的遗传基础，以及基因在疾病发生、发展和治疗中发挥的作用，相关成果可用于开发评估患病风险、指导疾病诊疗的新产品。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
MYGN vs QDEL — 直观对比
营收规模更大
QDEL
是对方的3.3倍
$209.8M
营收增速更快
MYGN
高出3.4%
-3.7%
两年增速更快
MYGN
近两年复合增速
-2.9%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $209.8M | $699.9M |
| 净利润 | — | $-733.0M |
| 毛利率 | 70.0% | — |
| 营业利润率 | -2.7% | -100.7% |
| 净利率 | — | -104.7% |
| 营收同比 | -0.4% | -3.7% |
| 净利润同比 | — | -3583.4% |
| 每股收益（稀释后） | $-0.09 | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MYGNQDEL
| Q4 25 | $209.8M | — | ||
| Q3 25 | $205.7M | $699.9M | ||
| Q2 25 | $213.1M | $613.9M | ||
| Q1 25 | $195.9M | $692.8M | ||
| Q4 24 | $210.6M | $707.8M | ||
| Q3 24 | $213.3M | $727.1M | ||
| Q2 24 | $211.5M | $637.0M | ||
| Q1 24 | $202.2M | $711.0M |
净利润MYGNQDEL
| Q4 25 | — | — | ||
| Q3 25 | $-27.4M | $-733.0M | ||
| Q2 25 | $-330.5M | $-255.4M | ||
| Q1 25 | $-100.0K | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $-22.1M | $-19.9M | ||
| Q2 24 | $-36.7M | $-147.7M | ||
| Q1 24 | $-26.0M | $-1.7B |
毛利率MYGNQDEL
| Q4 25 | 70.0% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 71.2% | — | ||
| Q1 25 | 68.5% | — | ||
| Q4 24 | 71.7% | — | ||
| Q3 24 | 70.2% | — | ||
| Q2 24 | 69.6% | — | ||
| Q1 24 | 68.1% | — |
营业利润率MYGNQDEL
| Q4 25 | -2.7% | — | ||
| Q3 25 | -11.3% | -100.7% | ||
| Q2 25 | -154.5% | -29.4% | ||
| Q1 25 | -14.8% | 4.7% | ||
| Q4 24 | -18.6% | -14.2% | ||
| Q3 24 | -9.4% | 2.1% | ||
| Q2 24 | -17.3% | -18.4% | ||
| Q1 24 | -13.8% | -247.3% |
净利率MYGNQDEL
| Q4 25 | — | — | ||
| Q3 25 | -13.3% | -104.7% | ||
| Q2 25 | -155.1% | -41.6% | ||
| Q1 25 | -0.1% | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | -10.4% | -2.7% | ||
| Q2 24 | -17.4% | -23.2% | ||
| Q1 24 | -12.9% | -239.9% |
每股收益（稀释后）MYGNQDEL
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.29 | $-10.78 | ||
| Q2 25 | $-3.57 | $-3.77 | ||
| Q1 25 | $0.00 | $-0.19 | ||
| Q4 24 | $-0.47 | $-2.54 | ||
| Q3 24 | $-0.24 | $-0.30 | ||
| Q2 24 | $-0.41 | $-2.20 | ||
| Q1 24 | $-0.29 | $-25.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.6M | $98.1M |
| 总债务越低越好 | $119.9M | $2.5B |
| 股东权益账面价值 | $368.0M | $2.0B |
| 总资产 | $706.6M | $5.7B |
| 负债/权益比越低杠杆越低 | 0.33× | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资MYGNQDEL
| Q4 25 | $149.6M | — | ||
| Q3 25 | $145.4M | $98.1M | ||
| Q2 25 | $74.4M | $151.7M | ||
| Q1 25 | $91.8M | $127.1M | ||
| Q4 24 | $102.4M | $98.3M | ||
| Q3 24 | $99.9M | $143.7M | ||
| Q2 24 | $97.3M | $107.0M | ||
| Q1 24 | $104.3M | $78.5M |
总债务MYGNQDEL
| Q4 25 | $119.9M | — | ||
| Q3 25 | $119.5M | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益MYGNQDEL
| Q4 25 | $368.0M | — | ||
| Q3 25 | $372.8M | $2.0B | ||
| Q2 25 | $388.1M | $2.8B | ||
| Q1 25 | $704.9M | $3.0B | ||
| Q4 24 | $701.1M | $3.0B | ||
| Q3 24 | $731.7M | $3.2B | ||
| Q2 24 | $740.5M | $3.2B | ||
| Q1 24 | $760.0M | $3.3B |
总资产MYGNQDEL
| Q4 25 | $706.6M | — | ||
| Q3 25 | $728.1M | $5.7B | ||
| Q2 25 | $677.3M | $6.4B | ||
| Q1 25 | $1.0B | $6.5B | ||
| Q4 24 | $1.0B | $6.4B | ||
| Q3 24 | $1.1B | $6.8B | ||
| Q2 24 | $1.1B | $6.7B | ||
| Q1 24 | $1.1B | $6.7B |
负债/权益比MYGNQDEL
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.32× | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $10.6M | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-94.7M |
| 自由现金流率自由现金流/营收 | — | -13.5% |
| 资本支出强度资本支出/营收 | — | 7.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-153.1M |
8季度趋势，按日历期对齐
经营现金流MYGNQDEL
| Q4 25 | $10.6M | — | ||
| Q3 25 | $21.1M | $-45.5M | ||
| Q2 25 | $-13.6M | $-46.8M | ||
| Q1 25 | $-16.3M | $65.6M | ||
| Q4 24 | $6.6M | $63.7M | ||
| Q3 24 | $700.0K | $117.9M | ||
| Q2 24 | $2.6M | $-97.9M | ||
| Q1 24 | $-18.6M | $-700.0K |
自由现金流MYGNQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | $-94.7M | ||
| Q2 25 | — | $-84.3M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | — | $71.4M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | — | $-66.8M |
自由现金流率MYGNQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -9.4% |
资本支出强度MYGNQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 9.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MYGN
暂无分部数据
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
